Apyx Medical Corporation (NASDAQ:APYX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Apyx Medical Corporation (NASDAQ:APYX) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $6.50.

A number of equities analysts have weighed in on APYX shares. BTIG Research upgraded shares of Apyx Medical from a “neutral” rating to a “buy” rating and set a $6.00 price objective for the company in a research report on Wednesday, March 11th. Wall Street Zen cut shares of Apyx Medical from a “buy” rating to a “hold” rating in a research report on Sunday, April 26th. Craig Hallum upped their price objective on shares of Apyx Medical from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Apyx Medical in a research report on Friday, March 27th.

Institutional Investors Weigh In On Apyx Medical

A number of large investors have recently modified their holdings of APYX. AIGH Capital Management LLC acquired a new stake in Apyx Medical during the fourth quarter worth about $3,867,000. Huntleigh Advisors Inc. acquired a new stake in Apyx Medical during the fourth quarter worth about $827,000. Renaissance Technologies LLC increased its position in Apyx Medical by 37.2% during the first quarter. Renaissance Technologies LLC now owns 302,395 shares of the company’s stock worth $1,116,000 after purchasing an additional 82,000 shares during the last quarter. Sei Investments Co. increased its position in Apyx Medical by 298.6% during the first quarter. Sei Investments Co. now owns 598,255 shares of the company’s stock worth $2,208,000 after purchasing an additional 448,174 shares during the last quarter. Finally, Nwam LLC acquired a new stake in Apyx Medical during the first quarter worth about $47,000. Hedge funds and other institutional investors own 55.33% of the company’s stock.

Apyx Medical Stock Performance

NASDAQ:APYX opened at $4.11 on Friday. The company has a debt-to-equity ratio of 2.68, a quick ratio of 4.79 and a current ratio of 5.80. The company has a fifty day moving average of $3.98 and a two-hundred day moving average of $3.83. The stock has a market capitalization of $172.09 million, a PE ratio of -18.68 and a beta of 1.39. Apyx Medical has a fifty-two week low of $1.59 and a fifty-two week high of $5.08.

Apyx Medical (NASDAQ:APYX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.06. The company had revenue of $12.49 million during the quarter, compared to analysts’ expectations of $10.53 million. Apyx Medical had a negative net margin of 16.40% and a negative return on equity of 88.47%.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.